NAD Recommends Avadim Health, Inc. Discontinue Health-Related Claims for Theraworx Relief for Muscle and Joint Products; Advertiser to Appeal

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 

703.247.9330 /

New York, NY – October 21, 2020 – The National Advertising Division (NAD) of BBB National Programs determined that Avadim Health, Inc. (Avadim) did not provide a reasonable basis for health-related claims appearing on product packaging, in website and social media advertising and elsewhere, for its Theraworx Relief for Muscle Cramps and Spasm Foam (“Theraworx MCS”) and Theraworx Relief for Joint Discomfort & Inflammation Foam (“Theraworx JDI”) (collectively “Theraworx Relief Products”) which promise consumers that its Theraworx Relief Products, respectively, relieve and prevent muscle cramps and spasms including those associated with nocturnal cramps and restless legs syndrome, and relieve joint pain stemming from arthritis as well as moderate to severe joint inflammation.  The claims were challenged by Chattem, Inc., a Sanofi Company, maker of Icy Hot and Aspercreme. 

Therefore, NAD recommended that the advertiser discontinue its unsupported health-related, product effectiveness, endorsement, and superiority claims.  

Theraworx Relief Muscle Cramp & Spasm Foam Claims 

  • “Clinically proven to prevent foot and leg cramps when used daily.” 
  • “REDUCES the severity of symptoms associated with RLS [restless leg syndrome].” 
  • “PREVENTS cramps and spasms when used daily.” 
  • “RELEASES muscle tightness.” 
  • “RELIEVES muscle soreness.” 
  • “[Q]uickly relieves muscle cramps and even prevents them when used daily.” 
  • “Fast-acting muscle cramp and spasm relief.” 
  • “Use Theraworx Relief twice daily (in the morning and before bedtime) to prevent nighttime muscle cramps and spasms, or three times daily if you also experience cramps or spasms during the day.”   
  • “As soon as you feel a muscle cramp or spasm coming on, use Theraworx Relief to quickly release muscle tightness and reduce the soreness afterwards. There’s no limit to how many times you can apply it per day!” 
  • “In multiple clinical studies, Theraworx Relief has been proven to: Provide fast acting relief of muscle cramps and spasms, as well as post-cramp soreness -- most people get relief within minutes . . . [and] Reduce symptoms associated with restless leg syndrome (RLS).” 
  • “In a research study including patients diagnosed with RLS, Theraworx Relief was shown to reduce symptoms commonly associated with and accompanying RLS, including muscle cramps and spasms.” 
  • “Theraworx Relief for Muscle Cramps and Spasms can be used as a companion product to manage the leg cramps associated with many important, commonly prescribed medications.” 
  • “In a clinical study, participants noticed a significant reduction in the frequency of their leg & foot cramps within the first 2 weeks of daily use.” 
  • “Nothing Else Like It on the Shelves.” 

Theraworx Relief Joint Discomfort & Inflammation Foam Products Claims 

  • “Relieves arthritic, inflamed, sore, or overused joints.” 
  • “[S]tudied in patients with moderate-to severe joint inflammation.”  

NAD also recommended that the advertiser discontinue its claim that “health care professionals recommend” Theraworx products, discontinue the challenged endorsements (e.g., “Theraworx Relief is better than any product out there for leg cramps or spasms or even muscle soreness”), and avoid the use of any endorsement making unsupported claims.  

Finally, NAD recommended that the advertiser avoid making any comparative superiority claims reasonably conveying the message that its Theraworx Relief Products are more effective than other external analgesic OTC products, including the challenger’s Icy Hot and Aspercreme, or prescription medications. 

This challenge involved claims for two related homeopathic external muscle and joint relief products – Theraworx MCS with its active ingredient magnesium sulfate, and Theraworx JDI with its active ingredient olibanum - each of which comes with a compression garment. There are no FDA-approved OTC indications for the active ingredients in the advertiser’s products, and these ingredients have not been reviewed or found to be generally recognized as safe by the FDA to diagnose, treat, cure, prevent or mitigate any disease conditions. 

NAD noted that in order to support its claims, Avadim should demonstrate via competent and reliable scientific evidence that its Theraworx MCS product, when used as directed, not only relieves muscle cramps and spasms, including those associated with nocturnal cramps and restless leg syndrome, but prevents muscle cramps and spasms, and that its Theraworx JDI, relieves moderate to severe joint inflammation and pain due to arthritis and overused joints, after controlling for other confounding factors like a placebo effect. NAD carefully reviewed the studies submitted by Avadim in support of its health-related claims for both of its Theraworx Relief Products but determined that the evidence was not a good fit for such claims. Therefore, NAD concluded that the advertiser did not provide a reasonable basis for such claims and recommended that they be discontinued.  

With regard to the advertiser’s healthcare professional endorsements (“Healthcare Professionals Recommend Theraworx”), NAD noted that the advertiser presented no survey evidence of healthcare professionals (or pharmacists) to show that a substantial portion of healthcare professionals recommend its products. Further, NAD concluded that the FTC Endorsement Guides necessitate that the specific testimonials featured on the advertiser’s website be discontinued because these endorsements would be deceptive if made directly by the advertiser due to a lack of support for such claims. 

In its advertiser’s statement, Avadim stated that it will appeal the entirety of NAD’s decision to the National Advertising Review Board. 


About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

Latest News

Press Release

BBB National Programs National Advertising Division Launches Expedited Fast-Track SWIFT Lane Designed to Address Misleading Advertising Disclosures

New York, NY – November 9, 2021 – Mindful of recent Federal Trade Commission (FTC) actions, BBB National Programs today announced a new, streamlined lane of the expedited Fast-Track SWIFT challenge submission process, one designed specifically to address the prominence and sufficiency of...

Read the Release
Press Release

Media Advisory: FTC Commissioner Rebecca Slaughter to Keynote National Advertising Division “Future of Ad Law” 2021 Annual Conference

New York, NY – September 21, 2021 – In its 50th anniversary year, the National Advertising Division (NAD) of BBB National Programs will host the NAD 2021 Annual Conference virtually next week, running Wednesday, September 29 through Friday, October 1. Members of the media are invited to cover NAD 2021 with...

Read More
Press Release

Children’s Advertising Review Unit Issues Revised Guidelines for Responsible Advertising to Children, Effective January 1, 2022

McLean, VA – July 29, 2021 – BBB National Programs’ Children’s Advertising Review Unit (CARU) today announced the issuance of the revised CARU Advertising Guidelines, widely recognized industry standards to assure that advertising directed to children is not deceptive, unfair, or inappropriate for its intended...

Read the Press Release
Press Release

U.S.-Based BBB National Programs Announced as Winner for “Best Sectoral Initiative” by International Council of Advertising Self-Regulation

On 15 June 2021, the International Council for Advertising Self-Regulation (ICAS) announced the winners of its second edition of the ICAS Global Awards. The objective of the ICAS Awards is to reward initiatives that contribute to responsible marketing practices and a more effective and impactful...

Read the Press Release